B. Riley Wealth Advisors Inc. Sells 4,387 Shares of Stryker Co. (NYSE:SYK)

B. Riley Wealth Advisors Inc. lessened its stake in shares of Stryker Co. (NYSE:SYK) by 15.2% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 24,396 shares of the medical technology company’s stock after selling 4,387 shares during the quarter. B. Riley Wealth Advisors Inc.’s holdings in Stryker were worth $8,320,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Central Pacific Bank Trust Division bought a new position in Stryker in the first quarter valued at about $39,000. Accent Capital Management LLC purchased a new position in shares of Stryker in the fourth quarter worth approximately $60,000. Sachetta LLC grew its position in Stryker by 16.3% during the second quarter. Sachetta LLC now owns 242 shares of the medical technology company’s stock valued at $80,000 after buying an additional 34 shares during the period. Hazlett Burt & Watson Inc. raised its position in Stryker by 17.9% in the first quarter. Hazlett Burt & Watson Inc. now owns 264 shares of the medical technology company’s stock worth $94,000 after acquiring an additional 40 shares during the period. Finally, Rise Advisors LLC boosted its stake in shares of Stryker by 144.6% during the 1st quarter. Rise Advisors LLC now owns 274 shares of the medical technology company’s stock worth $98,000 after acquiring an additional 162 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Trading Down 0.3 %

Shares of SYK stock opened at $360.27 on Monday. The stock’s 50-day moving average price is $347.92 and its 200-day moving average price is $342.96. Stryker Co. has a 12-month low of $249.98 and a 12-month high of $374.63. The stock has a market capitalization of $137.29 billion, a price-to-earnings ratio of 41.13, a price-to-earnings-growth ratio of 2.78 and a beta of 0.91. The company has a current ratio of 1.68, a quick ratio of 0.95 and a debt-to-equity ratio of 0.51.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.79 by $0.02. The business had revenue of $5.42 billion for the quarter, compared to the consensus estimate of $5.40 billion. Stryker had a return on equity of 22.89% and a net margin of 16.12%. The company’s revenue was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.54 EPS. Equities research analysts predict that Stryker Co. will post 12 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be given a dividend of $0.80 per share. The ex-dividend date of this dividend is Monday, September 30th. This represents a $3.20 annualized dividend and a yield of 0.89%. Stryker’s dividend payout ratio (DPR) is currently 36.53%.

Analyst Ratings Changes

A number of equities analysts recently commented on SYK shares. Needham & Company LLC raised their target price on Stryker from $392.00 to $393.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $386.00 price objective on shares of Stryker in a research note on Wednesday, July 31st. Evercore ISI cut their price objective on Stryker from $370.00 to $365.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. StockNews.com cut shares of Stryker from a “buy” rating to a “hold” rating in a research note on Monday, September 16th. Finally, UBS Group upped their price target on shares of Stryker from $351.00 to $366.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and an average price target of $378.58.

Insiders Place Their Bets

In other Stryker news, CFO Glenn S. Boehnlein sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $333.00, for a total transaction of $6,660,000.00. Following the sale, the chief financial officer now directly owns 2,852 shares of the company’s stock, valued at $949,716. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, VP M Kathryn Fink sold 2,121 shares of the stock in a transaction on Friday, September 13th. The shares were sold at an average price of $370.00, for a total value of $784,770.00. Following the sale, the vice president now owns 10,042 shares of the company’s stock, valued at $3,715,540. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Glenn S. Boehnlein sold 20,000 shares of Stryker stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $333.00, for a total transaction of $6,660,000.00. Following the transaction, the chief financial officer now directly owns 2,852 shares of the company’s stock, valued at $949,716. The disclosure for this sale can be found here. Insiders sold 220,068 shares of company stock valued at $71,811,372 in the last three months. Corporate insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.